Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10294792" target="_blank" >RIV/00216208:11110/15:10294792 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/15:10294792
Result on the web
<a href="http://dx.doi.org/10.1002/ana.24339" target="_blank" >http://dx.doi.org/10.1002/ana.24339</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/ana.24339" target="_blank" >10.1002/ana.24339</a>
Alternative languages
Result language
angličtina
Original language name
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Original language description
ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switchingto either of these agents. MethodsUsing MSBase, a large international, observational, prospectively acquired cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing relapses or disability progression within the 6 months immediately preceding switch to either natalizumab or fingolimod. Quasi-randomization with propensity score-based matching was used to select subpopulations with comparable baseline characteristics. Relapse and disability outcomes were compared in paired, pairwise-censored analyses. ResultsOf the 792 included patients, 578 patients were matched (natalizumab, n=407; fingolimod, n=171). Mean on-study follow-up was 12 months. The annualized relapse rates decreased from 1.5 to 0.2 on nat
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT13237" target="_blank" >NT13237: Clinical and paraclinical markers of multiple sclerosis – description and prediction of disease activity</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of Neurology
ISSN
0364-5134
e-ISSN
—
Volume of the periodical
77
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
425-435
UT code for WoS article
000350456800007
EID of the result in the Scopus database
2-s2.0-84923772724